C225

(redirected from IMC-C225)

C225

A chimeric IgG antibody with a strong binding affinity for epidermal growth factor (EGF) receptor, which blocks ligand—EGF, TGF α, etc.—binding and inhibits cell proliferation. C225 made it through to Phase III trials, during which time it was renamed cetuximab (Erbitux), and has proved to be a blockbuster cancer drug for head and neck cancer, colorectal and other cancers.
References in periodicals archive ?
[13.] Overholser JP, Prewett MC, Hooper AT, Waksal HW, Hicklin DJ (2000) Epidermal growth factor receptor blockade by antibody IMC-C225 inhibits growth of a human pancreatic carcinoma xenograft in nude mice.
Enhanced anti-tumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts.
Future issues of Medical Update will feature excerpts of Post interviews with leading researchers and specialists, along with an investigation of the late-breaking results of ImClone's IMC-C225 and its ability to arrest growth in advanced pancreatic cancers.
Also in late stage clinical studies is IMC-C225, ImClone Systems' lead investigational cancer therapeutic.
Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts.
Treatment of pancreatic cancer xenografts with Erbitux (IMC-C225) anti-EGFR antibody, gemcitabine, and radiation.